Leukotriene Receptor
Leukotriene Receptor (cys-LTs) are a family of potent bioactive lipids that act through two structurally divergent G protein-coupled receptors, termed the CysLT1 and CysLT2 receptors. The cysteinyl leukotrienes LTC4, LTD4, and LTE4 are important mediators of human bronchial asthma. Leukotriene Receptor is a member of the superfamily of G protein-coupled receptors and uses a phosphatidylinositol-calcium second messenger system. Activation of CysLT1 by LTD4 results in contraction and proliferation of smooth muscle, oedema, eosinophil migration and damage to the mucus layer in the lung. Leukotriene receptor antagonists, called LTRAs for short, are a class of oral medication that is non-steroidal. They may also be referred to as anti-inflammatory bronchoconstriction preventors. LTRAs work by blocking a chemical reaction that can lead to inflammation in the airways.
Leukotriene Receptor Isoform Specific Products
All Product Categories
-
Leukotriene Receptor Inhibitors
(66)
View all products
-
Leukotriene Receptor Agonists
(10)
View all products
-
Leukotriene Receptor Antagonists
(127)
View all products
-
Leukotriene Receptor Activators
(2)
View all products
-
Leukotriene Receptor Control
(1)
View all products
-
Leukotriene Receptor Substrate
(1)
View all products
-
Leukotriene Receptor Related Products (229)
Related Products (229)
-
Antibodies (1)
-
Leukotriene Receptor Isoform Comparison
-
SB 201146
0 ImagesCat. No.: HY-117854CAS No.: 141311-11-7SB 201146 is an LTB4 receptor antagonist with a potency range of 10 pM to 1 μM that plays a critical role in asthma-associated airway inflammation. Studies have focused on its effects on eosinophil survival, a hallmark of asthma pathology. Studies have shown that eosinophil-derived cysteinyl leukotrienes, including LTC4 and LTD4, as well as factors such as GM-CSF and fibronectin promote eosinophil survival. SB 201146 effectively reversed mast cell- and lymphocyte-induced eosinophil survival, highlighting its potential therapeutic role in disrupting the autocrine cysteinyl leukotriene pathway that maintains eosinophil viability. This antagonist also highlights the importance of LTB4 as a paracrine mediator that influences eosinophil survival in inflammatory settings such as asthma.
-
Moxilubant (Standard)
0 ImagesCat. No.: HY-106929RCAS No.: 146978-48-5Synonyms: CGS 25019C free base (Standard)Moxilubant (CGS 25019C free base) Standard is the analytical standard of Moxilubant (HY-106929). This product is intended for research and analytical applications. Moxilubant (CGS 25019C free base) is an orally active BLT1 antagonist. Moxilubant inhibits LTB4 signaling with a potency of 2-4 nM. Moxilubant blocks LTB4-induced neutrophil functions. Moxilubant inhibits ear edema and neutrophil infiltration in mice. Moxilubant can be used in research related to chronic obstructive pulmonary disease.
-
CysLT1/2 receptor antagonist-1
0 ImagesCat. No.: HY-184812CAS No.: 1637756-67-2CysLT1/2 receptor antagonist-1 is a dual CysLT1 and CysLT2 receptor antagonist with IC50 values of 0.044 μM (CysLT1) and 0.17 μM (CysLT2). CysLT1/2 receptor antagonist-1 can be used for the research of bronchial asthma.
-
Q8
0 ImagesCat. No.: HY-127113CAS No.: 1541762-55-3
-
LY203647
0 ImagesCat. No.: HY-120486CAS No.: 122009-61-4LY203647 is an orally active antagonist for leukotriene receptor LTD4 and LTE4. LY203647 can be used in research about asthma and other inflammation diseases.
-
RG-7152
0 ImagesCat. No.: HY-19109CAS No.: 107813-63-8RG-7152 is a tetrazolyl-substituted leukotriene D4 receptor antagonist that can induce peroxisomal β-oxidation and peroxisome bifunctional enzymes (PBEs) in hepatocytes in various animal models. It has been shown to significantly increase PBE levels and β-oxidation activity in rat and mouse liver homogenates, while smaller effects were observed in guinea pigs and monkeys and no effect in dogs. In vitro studies have also shown that it can induce PBEs comparable to clofibric acid, indicating its potential as a peroxisome proliferator.
-
Nedocromil (Standard)
0 ImagesSynonyms: FPL 59002 (Standard)Nedocromil (Standard) is the analytical standard of Nedocromil. This product is intended for research and analytical applications. Nedocromil suppresses the action or formation of multiple mediators, including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2).
-
Zafirlukast-d7
0 ImagesCat. No.: HY-17492SCAS No.: 1217174-18-9Zafirlukast-d7 is the deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
-
Ricinelaidic acid
0 ImagesRicinelaidic acid, a 12-hydroxy fatty acid，is a leukotriene B4 (LTB4) receptor antagonist with the Ki of 2 μM in porcine neutrophil membranes. Ricinelaidic acid inhibits chemotaxis and calcium flux induced by LTB4 in isolated human neutrophils (IC50=10 and 7 μM, respectively). Ricinelaidic acid inhibits bronchoconstriction induced by LTB4 in rats.
-
CGP-35949 sodium
0 ImagesCat. No.: HY-19041CAS No.: 111130-13-3CGP-35949 sodium is a LTD4 antagonist with phospholipase inhibitory activity. CGP-35949 sodium can be used for research of asthma.
-
LY290324
0 ImagesCat. No.: HY-120755CAS No.: 146554-87-2LY290324 is a potent and orally active leukotriene D4 (LTD4) antagonist. LY290324 reduces LTC4, LTD4 and LTE4 (HY-113465)-induced bronchospasm. LY290324 has the potential for the research of antigen-induced bronchospasm.
-
Zafirlukast-d6
0 ImagesCat. No.: HY-17492S3CAS No.: 1109278-84-3Synonyms: ICI 204219-d6Zafirlukast-d6 is deuterated labeled Zafirlukast (HY-17492). Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
-
Darbufelone mesylate (Standard)
0 ImagesCat. No.: HY-101438ARCAS No.: 139340-56-0Synonyms: CI-1004 mesylate (Standard)Darbufelone (mesylate) (Standard) is the analytical standard of Darbufelone (mesylate) (HY-101438A). This product is intended for research and analytical applications. Darbufelone mesylate (CI-1004 mesylate) is a dual inhibitor of cellular PGF2α and LTB4 production. Darbufelone potently inhibits PGHS-2 (IC50 = 0.19 μM) but is much less potent with PGHS-1 (IC50= 20 μM).
-
ZK-158252
0 ImagesCat. No.: HY-122175CAS No.: 162362-36-9ZK-158252 is a leukotriene B4 type-2 receptor (BLT2) antagonist.
-
Maresin conjugates in tissue regeneration 1
0 ImagesCat. No.: HY-125408CAS No.: 1784701-61-6Synonyms: MCTR1Maresin conjugates in tissue regeneration 1 (MCTR1) is a potent cytokine of pro-resolving mediating maresin conjugates in tissue regeneration (MCTR), which reduces the inflammatory response and promotes tissue regeneration. Maresin conjugates in tissue regeneration 1 antagonize LTD4-stimulated vascular responses.
-
L-648051
0 ImagesCat. No.: HY-122149CAS No.: 91541-18-3L-648051 is a leukotriene D4 receptor (LTD4) antagonist. L-648051 plays an important role in arrhythmias.
-
LY 292728
0 ImagesCat. No.: HY-117706CAS No.: 153034-77-6LY 292728 is a potent leukotriene B4 (LTB4) receptor antagonist. LY 292728 binds to human neutrophils with a Ki of 0.47 nM and binds to guinea pig lung membranes with a Ki of 0.04 nM.
-
γ-Linolenic acid ethyl ester (Standard)
0 ImagesCat. No.: HY-108396RCAS No.: 31450-14-3Synonyms: Ethyl γ-linolenate (Standard)γ-Linolenic acid ethyl ester (Standard) is the analytical standard of γ-Linolenic acid ethyl ester (HY-108396). This product is intended for research and analytical applications. γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B4 receptor 4 (LTB4) antagonist.
-
Leukotriene B4-d5
0 ImagesCat. No.: HY-107608S1Synonyms: LTB4-d5Leukotriene B4-d5 (LTB4-d5) is deuterium labeled Leukotriene B4. Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases. Leukotriene B4 is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.
-
RG-12525 (Standard)
0 ImagesCat. No.: HY-101676RCAS No.: 120128-20-3Synonyms: NID 525 (Standard)RG-12525 (Standard) is the analytical standard of RG-12525 (HY-101676). This product is intended for research and analytical applications. RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC50s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC50 of appr 60 nM and a potent inhibitor of CYP3A4, with a Ki value of 0.5 μM.
